Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05990192 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

Study acronym: SOPRANO
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Jun 30, 2027 to Dec 31, 2027v6 Show 4 more changesShow less
    • Study sites: 5 to 7
    • Eligibility criteria expanded, about 60 words
    • Secondary endpoints: details revised at 9 of 10 entries
    • Study description shortened, about 2 words
  2. Study sites: 3 to 5v5
  3. Study sites: 2 to 3v4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 2024 to Jun 20, 2024
    • Site details revised at 2 of 2 sites
    v3
  5. Primary and study completion dates: Sep 2026 to Jun 30, 2027
    • Start date: Sep 2023 to Jan 2024
    • Eligibility criteria revised
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
SOPRANO is a multi-centre phase II trial designed to assess the impact of SBRT with or without continuing treatment with a PARP inhibitor (PARPi) for patients with oligometastatic or oligoprogressive ovarian, fallopian tube and primary peritoneal carcinoma. SOPRANO will also establish the feasibility and acceptability of delivering SBRT in this setting.
Trial Details
NCT Number NCT05990192
Lead Sponsor Institute of Cancer Research, United Kingdom
Collaborators: Royal Marsden NHS Foundation Trust
Conditions
(from sponsor)		 Ovarian Cancer Recurrent
Related terms Ovarian Neoplasms
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov